- Full Year 2023 Ipsen SA Earnings Call TranscriptFeb 08, 2024MXN2285.02Earnings
- Ipsen SA Capital Markets Day TranscriptDec 07, 2023
- Ipsen SA to Discuss the ELATIVE Phase III Trial Results Call TranscriptNov 14, 2023
- Ipsen SA at Deutsche Bank ADR Investor Conference (Virtual) TranscriptNov 08, 2023
- Q3 2023 Ipsen SA Corporate Sales Call TranscriptOct 26, 2023
- Half Year 2023 Ipsen SA Earnings Call TranscriptJul 27, 2023MXN2285.02Earnings
- Genfit SA and Ipsen SA Announce Positive Results from Phase III ELATIVE® Trial of Elafibranor in Patients with Primary Biliary Cholangitis Call TranscriptJun 30, 2023
- Q1 2023 Ipsen SA Corporate Sales Call TranscriptApr 27, 2023
- Full Year 2022 Ipsen SA Earnings Call TranscriptFeb 09, 2023MXN2285.02Earnings
- Ipsen SA M&A Call TranscriptJan 09, 2023
- Q3 2022 Ipsen SA Corporate Sales Call TranscriptOct 27, 2022
- Half Year 2022 Ipsen SA Earnings Call TranscriptJul 28, 2022MXN2285.02Earnings
- Ipsen SA to Acquire Epizyme Inc Call TranscriptJun 27, 2022
- Q1 2022 Ipsen SA Corporate Sales Call TranscriptApr 27, 2022
- Full Year 2021 Ipsen SA Earnings Call TranscriptFeb 11, 2022MXN2285.02Earnings
- Ipsen SA Expanding the Scope in Rare Disease Investor and Analyst Conference Call TranscriptDec 17, 2021
- Ipsen SA at OTC Markets and Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptNov 16, 2021
- Q3 2021 Ipsen SA Corporate Sales Call TranscriptOct 21, 2021
- Half Year 2021 Ipsen SA Earnings Call TranscriptJul 29, 2021MXN2285.02Earnings
- Q1 2021 Ipsen SA Corporate Sales Call TranscriptApr 22, 2021
- Ipsen SA at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Ipsen SA Capital Markets Day TranscriptDec 01, 2020
- Q3 2020 Ipsen SA Corporate Sales Call TranscriptOct 22, 2020
- Half Year 2020 Ipsen SA Corporate Sales Call TranscriptJul 30, 2020
- Ipsen SA Annual Shareholders Meeting TranscriptMay 29, 2020
- Q1 2020 Ipsen SA Corporate Sales Call TranscriptApr 22, 2020
- Ipsen SA at PR Newswire and BetterInvesting (NAIC) Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptMar 18, 2020
- Full Year 2019 Ipsen SA Earnings Call TranscriptFeb 13, 2020Earnings
- Ipsen SA at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Half Year 2019 Ipsen SA Earnings Call TranscriptJul 25, 2019Earnings
- Ipsen SA Investor Day TranscriptMay 14, 2019
- Q1 2019 Ipsen SA Corporate Sales Call TranscriptApr 24, 2019
- Ipsen SA to acquire Clementia Pharmaceuticals Conference Call TranscriptFeb 25, 2019
- Full Year 2018 Ipsen SA Earnings Call TranscriptFeb 14, 2019Earnings
Ipsen SA to Discuss the ELATIVE Phase III Trial Results Call Transcript
Hello, and welcome to Ipsen's Investor Science call at AASLD. I'd now like to turn over to Craig Marks of Ipsen.
Hello, everyone. As you just heard, I'm Craig Marks, Vice President of Investor Relations at Ipsen. We're live in Boston, and it's a real pleasure to welcome you at Ipsen's Investor Science Conference Call here at the 2023 AASLD meeting. The plan for this call is to focus on the results from the elafibranor ELATIVE Phase III trial presented yesterday at the late-breaker session.
We plan to comment today only on the results of the trial. Commercial questions will be answered at next month's Capital Markets Day.
Next slide, please. This is our usual safe harbor statement. Next slide, please. I'd now like to introduce you to our 3 speakers today. Jennifer Schranz, Global Head of Rare Disease R&D, Ipsen will summarize our focus in rare disease and our extensive presence at AASLD over the past few days. Dr. Christopher Bowlus, Professor and Chief of the Division of Gastroenterology and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)